X4 Pharmaceuticals, Inc.
General ticker "XFOR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $453.7M (TTM average)
X4 Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 13.5%.
Estimated limits based on current volatility of 4.5%: low 2.50$, high 2.73$
Factors to consider:
- Total employees count: 45 (-68.5%) as of 2025
- Countries other than US accounted for 0.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Failure to achieve profitability, Need additional capital, Regulatory and compliance, Clinical trial failure, Manufacturing issues
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.38$, 8.31$]
- 2026-12-31 to 2027-12-31 estimated range: [1.59$, 5.85$]
Financial Metrics affecting the XFOR estimates:
- Positive: with PPE of -1.0 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Positive: 58.56 < Shareholder equity ratio, % of 64.14 <= 69.38
- Positive: Interest expense per share per price, % of 4.96 <= 10.35
- Positive: Inventory ratio change, % of -42.16 <= -3.92
- Positive: Investing cash flow per share per price, % of 4.56 > 2.08
- Positive: -28.70 < Return on assets ratio (scaled to [-100,100]) of -21.42
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term XFOR quotes
Long-term XFOR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $2.56MM | $35.11MM |
| Operating Expenses | $107.52MM | $38.96MM | $122.00MM |
| Operating Income | $-107.52MM | $-36.40MM | $-86.88MM |
| Non-Operating Income | $6.43MM | $-0.74MM | $7.72MM |
| Interest Expense | $5.78MM | $8.77MM | $8.88MM |
| R&D Expense | $72.02MM | $81.64MM | $72.72MM |
| Income(Loss) | $-101.09MM | $-37.14MM | $-79.16MM |
| Taxes | $0.08MM | $0.31MM | $0.04MM |
| Net Income(Loss)* | $-101.17MM | $-37.45MM | $-79.20MM |
| Stockholders Equity | $51.10MM | $22.15MM | $186.29MM |
| Inventory | $0.00MM | $2.82MM | $4.48MM |
| Assets | $147.26MM | $146.45MM | $290.46MM |
| Operating Cash Flow | $-96.51MM | $-130.90MM | $-85.62MM |
| Capital expenditure | $0.06MM | $7.33MM | $3.00MM |
| Investing Cash Flow | $-14.88MM | $66.99MM | $8.15MM |
| Financing Cash Flow | $88.52MM | $20.29MM | $238.63MM |
| Earnings Per Share** | $-17.07 | $-5.59 | $-1.87 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.